Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
Nine outpatients who met well-defined criteria for probable Alzheimer's disease (AD) and who had significant behavioral agitation failed to improve with neuroleptic therapy and were subsequently treated with carbamazepine. Five patients showed a clear improvement, and one patient an equivocal response according to clinical evaluation and Brief Psychiatric Rating Scale scores; those results suggests that carbamazepine may be useful to treat agitated AD patients who have not previously responded to neuroleptics and patients with other organic mental syndromes.
Gleason
R P
RP
Department of Psychiatry, University of Southern California School of Medicine, Los Angeles.
Schneider
L S
LS
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011595:Psychomotor Agitation / Q000188:drug therapy*
D014150:Antipsychotic Agents; D002220:Carbamazepine